6801
document
Clomipramine versus haloperidol in the treatment of autistic disorder : a double-blind , placebo-controlled , crossover study . Clomipramine , haloperidol , and placebo were compared with baseline in the treatment of autism , and overall outcome , specific symptoms , and side effects were examined . It was hypothesized that clomipramine would be better tolerated than haloperidol and prove superior on a measure of stereotypy . Individuals with a DSM-IV diagnosis of autistic disorder ( mean age , 16.3 years ; range , 10-36 years ) were randomly assigned , by using a Latin square design , to the following 7-week trials : placebo , clomipramine ( mean daily dose , 128.4 mg ; range , 100-150 mg ) , or haloperidol ( mean daily dose , 1.3 mg ; range , 1-1.5 mg ) . Data on 36 subjects were analyzed and taken together ; the results favored haloperidol . In those patients who were able to complete a full therapeutic trial , clomipramine proved comparable to haloperidol in terms of improvement compared with baseline . However , significantly fewer individuals receiving clomipramine versus haloperidol were able to complete the trial ( 37.5 % vs. 69.7 % , respectively ) for reasons related to both side effects and efficacy or behavior problems . In the intent-to-treat sample , which is perhaps more clinically relevant , only haloperidol proved superior to baseline on a global measure of autistic symptom severity , as well as specific measures for irritability and hyperactivity . Clomipramine did not seem more effective on a measure of stereotypy , nor was it better tolerated .
6802
Intervention_Pharmacological
Clomipramine versus haloperidol
6803
Intervention_Control
placebo-controlled
6804
Intervention_Pharmacological
Clomipramine , haloperidol
6805
Intervention_Control
placebo
6806
Intervention_Pharmacological
clomipramine
6807
Intervention_Pharmacological
haloperidol
6808
Intervention_Control
placebo
6809
Intervention_Pharmacological
clomipramine
6810
Intervention_Pharmacological
haloperidol
6811
Intervention_Pharmacological
haloperidol .
6812
Intervention_Pharmacological
clomipramine
6813
Intervention_Pharmacological
haloperidol
6814
Intervention_Pharmacological
clomipramine
6815
Intervention_Pharmacological
haloperidol
6816
Intervention_Pharmacological
haloperidol
6817
Intervention_Pharmacological
Clomipramine
6818
Outcome_Mental
overall outcome
6819
Outcome_Mental
specific symptoms
6820
Outcome_Adverse-effects
side effects
6821
Outcome_Physical
improvement
6822
Outcome_Adverse-effects
side effects
6823
Outcome_Other
efficacy
6824
Outcome_Mental
behavior problems
6825
Outcome_Mental
autistic symptom severity
6826
Outcome_Mental
irritability and hyperactivity
6827
Participant_Condition
autistic disorder :
6828
Participant_Condition
autism
6829
Participant_Sample-size
36